|
|
|
|
|
|
| Clinical Treatments Take Advantage of Both Gantry Mounted Cone Beam CT and Intensity Modulated Proton Therapy |
TOKYO, May 20, 2016 - (JCN Newswire) - Hokkaido University and Hitachi, Ltd.(TSE:6501, "Hitachi") have jointly developed an advanced technique to treat moving targets with proton beam therapy. This project was awarded a grant in 2010 under the Funding Program for World-Leading Innovative R&D on Science and Technology (the "FIRST Program"), a national project sponsored by the Japanese government. This new technique is now being clinically used with two additional capabilities - Cone Beam CT ("CBCT") and Intensity Modulated Proton Therapy ("IMPT").
Proton beam therapy (PBT) is an advanced type of cancer radiotherapy. Protons, the atomic nuclei of hydrogen, are accelerated to high speed and their energy is concentrated onto tumors. The superb characteristics of proton beams allow patients to maintain their normal lifestyles during treatment as it is painless and impact to the body's normal functions are minimized. PBT has thus attracted attention as a cutting-edge therapy for treating cancer whilst maintaining patients' quality of life ("QOL"). As these characteristics enable precise dose concentration, PBT can be easily applied to stationary targets such as brain tumors. Treatment however, of tumors in the torso such as those in the lung or liver which move due to respiration, require special care - and thus the combination of PBT with real-time tracking to target moving tumors has been highly anticipated.
Hokkaido University Hospital began treating patients with Spot Scanning proton beam therapy in March of 2014 and by December of that year had begun treating patients with Real-Time image Gated Proton Beam Therapy ("RGPT"). Since then, RGPT has been used in approximately 40% of treatments involving the liver and prostate and 10% of those involving the lung and pancreas. Over 80% of all treatments at the hospital now incorporate RGPT.
1) Gantry Mounted CBCT
To further improve the accuracy of PBT, there is a constant need for improved imaging of the internal structure of the tumor region. When information on the location of bone is taken from traditional orthogonal x-rays and the motion of tumors is captured by RGPT and then combined with the ability to identify healthy tissue surrounding a tumor, particularly the location and shape of soft tissue, it allows for a greater therapeutic dose to be directed at the tumor while significantly reducing the risk of irradiating healthy tissue. As a result, the ability to obtain this information immediately prior to treatment is increasingly being recognized as critical.
The rotating gantry mounted CBCT system, jointly developed by Hokkaido University and Hitachi, provides three-dimensional anatomical images of patients, at isocenter immediately prior to being treated, dramatically increasing the precision of the treatments. The CBCT system is also capable of highly accurate positioning even without the use of RGPT. After being approved for marketing under Japan's Pharmaceutical Affairs Law in March of 2015, the system was clinically put to use in October of the same year. Since then, 20 patients have been treated with the CBCT-equipped system and more patients are expected to benefit as clinical treatments continue.
Hokkaido University Hospital and Hitachi will continue to work together on a project titled Development of Medical Devices and Systems for Advanced Medical Services funded by the Japan Agency for Medical Research and Development (AMED) to further advance RGPT.
2) Intensity Modulated Proton Therapy (IMPT)
Intensity Modulated Proton Therapy is a form of Spot Scanning proton therapy, where the energies of proton beams directed from various angles are manipulated so that tumors of complex shapes can be precisely irradiated while minimizing the effect of radiation to surrounding healthy tissues.
Hokkaido University Hospital has collaborated with Hitachi in optimizing its treatment planning system to work seamlessly with IMPT for moving targets. By combining robust optimization designed to address inherent challenges in particle therapy treatments such as range uncertainties and treatment planning setup uncertainties with the tight dose distribution achieved through IMPT, the impact of moving targets can be minimized.
In August 2015, clinical use of IMPT began and has since been used for prostate, liver head & neck, and pediatric treatments. Plans are underway to further increase the number of treatable tumor types in accordance to accepted guidelines.
This announcement will be made at the upcoming 55th Annual Particle Therapy Co-Operative Group Meeting (PTCOG55) held in Prague, Czech Republic from May 22-28.
Hokkaido University Hospital, with their experience in radiation therapy and Hitachi, with their expertise in engineering design have combined their respective strengths in medicine and technology to offer cutting edge technology for cancer patients within the growing global market of proton beam therapy. Both organizations are committed to continued research and development to improve the quality of life of cancer patients through advanced proton beam therapy.
Contact:
Hitachi Ltd
Corporate Communications
Tel: +81-3-3258-1111
Topic: Press release summary
Source: Hitachi, Ltd.
Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
| Hitachi, Ltd. Related News |
|
| Friday, 5 April 2024, 17:15 JST |
| Hitachi Energy and SP Energy Networks to boost renewable energy flow |
|
| Friday, 5 April 2024, 17:00 JST |
| Hitachi Selected as "Excellent TCFD Disclosure" by GPIF's External Asset Managers for the Third Consecutive Year |
|
| Tuesday, 26 March 2024, 19:04 JST |
| JFE Steel and Hitachi Jointly Started Providing Solutions for the Steel Industry |
|
| Friday, 22 March 2024, 16:04 JST |
| Hitachi Selected as CDP Supplier Engagement Leader for the Third Consecutive Year |
|
| Tuesday, 19 March 2024, 19:11 JST |
| Hitachi Collaborates with NVIDIA to Accelerate Digital Transformation with Generative AI |
|
| More news >> |
|
|
|
